Journal of Clinical Oncology, Vol 25, No 7 (March 1), 2007: pp. 884-896
© 2007 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2006.06.3602
Sunitinib: From Rational Design to Clinical Efficacy
Laura Q.M. Chow,
S. Gail Eckhardt
From the Department of Medical Oncology, University of Colorado Health Sciences Center, Aurora, CO
Address reprint requests to S. Gail Eckhardt, MD, University of Colorado Cancer Center (Fitzsimons site), PO Box 6511 Campus Box 8117, Aurora, CO 80045; e-mail: Gail.eckhardt{at}uchsc.edu
Sunitinib (SU011248) is an oral small molecular tyrosine kinase inhibitor that exhibits potent antiangiogenic and antitumor activity. Tyrosine kinase inhibitors such as SU6668 and SU5416 (semaxanib) demonstrated poor pharmacologic properties and limited efficacy; therefore, sunitinib was rationally designed and chosen for its high bioavailability and its nanomolar-range potency against the antiangiogenic receptor tyrosine kinases (RTKs)vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR). Sunitinib inhibits other tyrosine kinases including, KIT, FLT3, colony-stimulating factor 1 (CSF-1), and RET, which are involved in a number of malignancies including small-cell lung cancer, GI stromal tumors (GISTs), breast cancer, acute myelogenous leukemia, multiple endocrine neoplasia types 2A and 2B, and familial medullary thyroid carcinoma. Sunitinib demonstrated robust antitumor activity in preclinical studies resulting not only in tumor growth inhibition, but tumor regression in models of colon cancer, nonsmall-cell lung cancer, melanoma, renal carcinoma, and squamous cell carcinoma, which were associated with inhibition of VEGFR and PDGFR phosphorylation. Clinical activity was demonstrated in neuroendocrine, colon, and breast cancers in phase II studies, whereas definitive efficacy has been demonstrated in advanced renal cell carcinoma and in imatinib-refractory GISTs, leading to US Food and Drug Administration approval of sunitinib for treatment of these two diseases. Studies investigating sunitinib alone in various tumor types and in combination with chemotherapy are ongoing. The clinical benchmarking of this small-molecule inhibitor of members of the split-kinase domain family of RTKs will lead to additional insights regarding the biology, potential biomarkers, and clinical utility of agents that target multiple signaling pathways in tumor, stromal, and endothelial compartments.
Terms in blue are defined in the glossary, found at the end of this article and online at www.jco.org.
Authors disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike Complore Connotea Del.icio.us Digg Facebook Reddit Technorati Twitter What's this?
Related Correspondence
- Sunitinib Malate and Multiple Receptor Tyrosine Kinases Inhibitors: Are They Also Novel Drugs for Chronic and Neurophatic Pain?
Luigi Di Lorenzo
JCO 2007 25: 2858-2859
[Full Text]
- Sunitinib Malate and Multiple Receptor Tyrosine Kinases Inhibitors: Are They Also Novel Drugs for Chronic and Neurophatic Pain?
Luigi Di Lorenzo
JCO 2007 25: 2858-2859
[Full Text]
This article has been cited by other articles:

|
 |

|
 |
 
S. George, P. Merriam, R. G. Maki, A. D. Van den Abbeele, J. T. Yap, T. Akhurst, D. C. Harmon, G. Bhuchar, M. M. O'Mara, D. R. D'Adamo, et al.
Multicenter Phase II Trial of Sunitinib in the Treatment of Nongastrointestinal Stromal Tumor Sarcomas
J. Clin. Oncol.,
July 1, 2009;
27(19):
3154 - 3160.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. X. Zhu, D. V. Sahani, D. G. Duda, E. di Tomaso, M. Ancukiewicz, O. A. Catalano, V. Sindhwani, L. S. Blaszkowsky, S. S. Yoon, J. Lahdenranta, et al.
Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study
J. Clin. Oncol.,
June 20, 2009;
27(18):
3027 - 3035.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Burkitt, S. Y. Chun, D. T. Dang, and L. H. Dang
Targeting both HIF-1 and HIF-2 in human colon cancer cells improves tumor response to sunitinib treatment
Mol. Cancer Ther.,
May 1, 2009;
8(5):
1148 - 1156.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Xin, C. Zhang, A. Herrmann, Y. Du, R. Figlin, and H. Yu
Sunitinib Inhibition of Stat3 Induces Renal Cell Carcinoma Tumor Cell Apoptosis and Reduces Immunosuppressive Cells
Cancer Res.,
March 15, 2009;
69(6):
2506 - 2513.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H.-C. J. Shen, M. He, A. Powell, A. Adem, D. Lorang, C. Heller, A. C. Grover, K. Ylaya, S. M. Hewitt, S. J. Marx, et al.
Recapitulation of Pancreatic Neuroendocrine Tumors in Human Multiple Endocrine Neoplasia Type I Syndrome via Pdx1-Directed Inactivation of Men1
Cancer Res.,
March 1, 2009;
69(5):
1858 - 1866.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Shukla, R. W. Robey, S. E. Bates, and S. V. Ambudkar
Sunitinib (Sutent, SU11248), a Small-Molecule Receptor Tyrosine Kinase Inhibitor, Blocks Function of the ATP-Binding Cassette (ABC) Transporters P-Glycoprotein (ABCB1) and ABCG2
Drug Metab. Dispos.,
February 1, 2009;
37(2):
359 - 365.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Jimenez, M. E. Cabanillas, L. Santarpia, E. Jonasch, K. L. Kyle, E. A. Lano, S. F. Matin, R. F. Nunez, N. D. Perrier, A. Phan, et al.
Use of the Tyrosine Kinase Inhibitor Sunitinib in a Patient with von Hippel-Lindau Disease: Targeting Angiogenic Factors in Pheochromocytoma and Other von Hippel-Lindau Disease-Related Tumors
J. Clin. Endocrinol. Metab.,
February 1, 2009;
94(2):
386 - 391.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Stacchiotti, E. Tamborini, A. Marrari, S. Brich, S. A. Rota, M. Orsenigo, F. Crippa, C. Morosi, A. Gronchi, M. A. Pierotti, et al.
Response to Sunitinib Malate in Advanced Alveolar Soft Part Sarcoma
Clin. Cancer Res.,
February 1, 2009;
15(3):
1096 - 1104.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. G. Hollingshead
Antitumor Efficacy Testing in Rodents
J Natl Cancer Inst,
November 5, 2008;
100(21):
1500 - 1510.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Tomoda, F. Moatamed, F. Naeim, J. M. Hershman, and M. Sugawara
Indomethacin Inhibits Cell Growth of Medullary Thyroid Carcinoma by Reducing Cell Cycle Progression into S Phase
Experimental Biology and Medicine,
November 1, 2008;
233(11):
1433 - 1440.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. E. Hutson, R. A. Figlin, J. G. Kuhn, and R. J. Motzer
Targeted Therapies for Metastatic Renal Cell Carcinoma: An Overview of Toxicity and Dosing Strategies
Oncologist,
October 1, 2008;
13(10):
1084 - 1096.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. L. Telli, R. M. Witteles, G. A. Fisher, and S. Srinivas
Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate
Ann. Onc.,
September 1, 2008;
19(9):
1613 - 1618.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. I. Rini, M. D. Michaelson, J. E. Rosenberg, R. M. Bukowski, J. A. Sosman, W. M. Stadler, T. E. Hutson, K. Margolin, C. S. Harmon, S. E. DePrimo, et al.
Antitumor Activity and Biomarker Analysis of Sunitinib in Patients With Bevacizumab-Refractory Metastatic Renal Cell Carcinoma
J. Clin. Oncol.,
August 1, 2008;
26(22):
3743 - 3748.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. S. Hong, S. B. Reddy, V. G. Prieto, J. J. Wright, N. M. Tannir, P. R. Cohen, A. H. Diwan, H. L. Evans, and R. Kurzrock
Multiple Squamous Cell Carcinomas of the Skin After Therapy With Sorafenib Combined With Tipifarnib
Arch Dermatol,
June 1, 2008;
144(6):
779 - 782.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Efferth, V. B. Konkimalla, Y.-F. Wang, A. Sauerbrey, S. Meinhardt, F. Zintl, J. Mattern, and M. Volm
Prediction of Broad Spectrum Resistance of Tumors towards Anticancer Drugs
Clin. Cancer Res.,
April 15, 2008;
14(8):
2405 - 2412.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. L. Showalter, J. M. Lloyd, D. T. Glassman, and A. C. Berger
Extra-Gastrointestinal Stromal Tumor of the Pancreas: Case Report and a Review of the Literature
Arch Surg,
March 1, 2008;
143(3):
305 - 308.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Azizi, A. Chedid, and S. Oudard
Home Blood-Pressure Monitoring in Patients Receiving Sunitinib
N. Engl. J. Med.,
January 3, 2008;
358(1):
95 - 97.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Suwattee, S. Chow, B. C. Berg, and E. M. Warshaw
Sunitinib: A Cause of Bullous Palmoplantar Erythrodysesthesia, Periungual Erythema, and Mucositis
Arch Dermatol,
January 1, 2008;
144(1):
123 - 125.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. J. Saylor and T. R. Reid
Tumor Lysis Syndrome After Treatment of a Gastrointestinal Stromal Tumor With the Oral Tyrosine Kinase Inhibitor Sunitinib
J. Clin. Oncol.,
August 10, 2007;
25(23):
3544 - 3546.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Di Lorenzo
Sunitinib Malate and Multiple Receptor Tyrosine Kinases Inhibitors: Are They Also Novel Drugs for Chronic and Neurophatic Pain?
J. Clin. Oncol.,
July 1, 2007;
25(19):
2858 - 2859.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Q.M. Chow and S. G. Eckhardt
In Reply
J. Clin. Oncol.,
July 1, 2007;
25(19):
2859 - 2861.
[Full Text]
[PDF]
|
 |
|
|